FDA APPROVES MODERNA’S FIRST-EVER mRNA FLU SHOT DESPITE 75.3% ADVERSE REACTION RATE

According to the FDA briefing document, severe systemic reactions were 4× MORE COMMON with the mRNA flu shot than with the traditional flu shot. by Nicolas Hulscher, MPH In a dark day for MAHA, the FDA has approved Moderna’s mFLUSIVA for adults 50 and older, making it the first seasonal mRNA influenza injection authorized in the United States. Adults ages 50–64 received traditional approval, while adults 65 and older received accelerated approval based largely on antibody responses. The FDA’s